Alzheimer's treatment with ultrasound technology
19 March, 2015 by Lauren DavisUniversity of Queensland researchers have discovered that non-invasive ultrasound technology can be used to treat Alzheimer's disease and restore memory in mice, breaking apart the neurotoxic amyloid-β (Aβ) plaques that result in cognitive decline.
NCRIS funding secured
19 March, 2015 by Susan WilliamsonThe government has guaranteed a future for the National Collaborative Research Infrastructure Strategy, at least in the short term.
Pancreatic cancer researcher is NSW Woman of the Year
11 March, 2015Pancreatic cancer researcher Professor Minoti Apte OAM has been announced 2015 NSW Woman of the Year by Premier Mike Baird and Minister for Women Pru Goward.
Novogen candidate kills brain cancer stem cells
04 March, 2015Drug development company Novogen (ASX:NRT) has announced the results of a study in which one of its lead candidate products, TRXE-009, successfully killed a library of patient-derived brain cancer cells.
New baseline biomarkers in Bionomics cancer trial
03 March, 2015Bionomics (ASX:BNO) has revealed new data from the DisrupTOR-1 trial of its anticancer candidate BNC105 in patients with metastatic renal cancer.
New drug candidate on trial for early-stage Alzheimer's
27 February, 2015 by Susan WilliamsonBiotech company Actinogen Medical (ASX: ACW) is progressing a phase 1 trial on its lead drug candidate, Xanamem, which it is hoped will provide a much-needed new treatment option for people with early-stage Alzheimer's disease.
Prescient nabs two US patents for cancer drug
23 February, 2015 by Dylan Bushell-EmblingPrescient Therapeutics (ASX:PTX) has secured two new US patents for PTX-200, a drug candidate with potential applications in platinum-resistant ovarian and other cancers.
Patrys gets new EU patent for PAT-SM6
20 February, 2015 by Dylan Bushell-EmblingPatrys (ASX:PAB) has secured a third European patent - its ninth globally - covering PAT-SM6, an anticancer candidate with potential applications in a wide range of cancers.
Sirtex profit grows 58% in 1H15
18 February, 2015 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has reported a 58.1% increase in net profit for the first half of FY15 as a result of stronger sales of its SIR-Spheres microspheres.
Medvet licenses cell line for cancer antibody
17 February, 2015 by Dylan Bushell-EmblingMedvet Science has licensed the XL-99 cell line from ACYTE Biotech and plans to use the line for the development of a monoclonal antibody with applications in cancer diagnostics and treatment.
New head for NHMRC
11 February, 2015Immunologist and virologist Professor Anne Kelso AO has been appointed as the new chief executive officer of the National Health and Medical Research Council (NHMRC) and will take up the position in April.
Prescient acquires cancer biomarker p27
09 February, 2015 by Dylan Bushell-EmblingPrescient (ASX:PTX) has acquired the exclusive global rights to the p27 biomarker and plans to develop it as a companion diagnostic to cancer drug candidate PTX-100.
Patrys multiple melanoma trial faces delays
06 February, 2015 by Dylan Bushell-EmblingPatrys (ASX:PAB) expects to have to delay a planned trial of PAT-SM6 in multiple myeloma due to issues surrounding the manufacture of materials for the study.
Sienna Cancer Diagnostics names interim CEO
05 February, 2015 by Dylan Bushell-EmblingSienna Cancer Diagnostics has selected former Immune System Therapeutics CEO Dr Cliff Holloway to serve as interim chief executive while a permanent replacement is found.
Patrys's PAT-SM6 found safe in myeloma trial
04 February, 2015 by Dylan Bushell-EmblingPatrys's (ASX:PAB) PAT-SM6 anticancer candidate met its primary safety and tolerability endpoints during a phase I/IIa multiple myeloma trial.
